Loading clinical trials...

Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study | Clinical Trials | Clareo Health

RECRUITINGNA

Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study

NCT07128030•Universidad Rey Juan Carlos

View on ClinicalTrials.gov

Summary

The aim of this study was to evaluate the feasibility, safety, and acceptability of a supervised, combined moderate-intensity aerobic and resistance training program designed to reduce pain sensitization in BCS with persistent pain. Secondary objectives included assessing changes in pain intensity, somatosensory sensitivity, and temporal summation, while tertiary objectives focused on improvements in quality of life and functional capacity.

Eligibility

Age

All ages

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Adult women diagnosed with stage I-III breast cancer
•Completion of active treatment (surgery, chemotherapy, and/or radiotherapy) at least 6 months prior to enrollment
•Presence of persistent pain or altered sensation in the upper quadrant of the affected limb related to oncologic treatment

Exclusion Criteria

•Bilateral breast cancer
•Locoregional recurrence
•Other malignancies
•Pre-existing pain not related to cancer treatment
•Neurological or cognitive disorders
•Non-Spanish speakers
•Contraindications to moderate-intensity physical activity

Locations (1)

Universidad Rey Juan Carlos

Madrid, Spain

Key Dates

Start Date

August 23, 2025

Primary Completion Date

February 23, 2026

Completion Date

February 23, 2026

Last Updated

November 24, 2025

Enrollment

ESTIMATED participants

Conditions

Exercise TrainingBreast CancerPain Management

Interventions

Exercise

OTHER

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Moderate-Intensity Exercise and Pain Sensitization in Breast Cancer Survivors: A Case-Based Study

Inclusion Criteria

Exclusion Criteria

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer